Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
← catalyst calendarSponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
80estimated
Sites
23
Countries
Australia, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-17 | actual | When the study began enrolling |
| Primary completion | 2026-08-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypochondroplasia
Interventions
- Drug: Vosoritide — also filed as Modified recombinant human C-type natriuretic peptide
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in annualized growth velocity (AGV) at Week 52 versus placebo
measured At week 52
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed